Search Results - "Soper, J T"

Preoperative quality of life and surgical outcomes in gynecologic oncology patients: A new predictor of operative risk? by Doll, K.M, Snavely, A.C, Kalinowski, A, Irwin, D.E, Bensen, J.T, Bae-Jump, V, Boggess, J.F, Soper, J.T, Brewster, W.R, Gehrig, P.A

“…Abstract Objective Quality of life (QoL) for women with gynecologic malignancies is predictive of chemotherapy related toxicity and overall survival but has…”
Get full text

Oral Medroxyprogesterone Acetate in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Dose-Response Study by the Gynecologic Oncology Group by THIGPEN, J. T, BRADY, M. F, ALVAREZ, R. D, ADELSON, M. D, HOMESLEY, H. D, MANETTA, A, SOPER, J. T, GIVEN, F. T

“…Progestins have definite activity against advanced or recurrent endometrial carcinoma. Both parenteral and oral progestins yield similar serum levels and…”
Get full text

Tamoxifen in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study by THIGPEN, Tate, BRADY, Mark F, HOMESLEY, Howard D, SOPER, John T, BELL, Jeffrey

“…In two large Gynecologic Oncology Group studies of patients with advanced or recurrent endometrial carcinoma and no previous systemic therapy, progestins have…”
Get full text

High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study by Lentz, S S, Brady, M F, Major, F J, Reid, G C, Soper, J T

“…Progestins represent the most widely used form of endocrine therapy in advanced or recurrent endometrial carcinoma. Based on encouraging response rates in…”
Get more information

Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer by Berchuck, A, Kamel, A, Whitaker, R, Kerns, B, Olt, G, Kinney, R, Soper, J T, Dodge, R, Clarke-Pearson, D L, Marks, P

“…Previous studies have suggested that overexpression of HER-2/neu oncogene occurs in 15-40% of breast cancers and that overexpression is associated with poor…”
Get full text

The Outcome of Stage I–II Clinically and Surgically Staged Papillary Serous and Clear Cell Endometrial Cancers When Compared with Endometrioid Carcinoma by Cirisano, Frank D., Robboy, Stanley J., Dodge, Richard K., Bentley, Rex C., Krigman, Hannah R., Synan, Ingrid S., Soper, John T., Clarke-Pearson, Daniel L.

“…Purpose. The aim of this study was to compare survival and recurrence in clinical and surgical stage I–II papillary serous (PS), clear cell (CC), and…”
Get full text

Epidemiologic and Surgicopathologic Findings of Papillary Serous and Clear Cell Endometrial Cancers When Compared to Endometrioid Carcinoma by Cirisano, Frank D., Robboy, Stanley J., Dodge, Richard K., Bentley, Rex C., Krigman, Hannah R., Synan, Ingrid S., Soper, John T., Clarke-Pearson, Daniel L.

“…Purpose. The aim of this study was to identify similarities and differences in epidemiologic and surgicopathologic staging results for papillary serous (PS)…”
Get full text

Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer by Kohler, M F, Marks, J R, Wiseman, R W, Jacobs, I J, Davidoff, A M, Clarke-Pearson, D L, Soper, J T, Bast, Jr, R C, Berchuck, A

“…The p53 gene encodes a nuclear phosphoprotein present in low levels in normal human cells. The wild-type form of this protein functions to restrain…”
Get more information

Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer by Alvarez Secord, A, Jones, E L, Hahn, C A, Petros, W P, Yu, D, Havrilesky, L J, Soper, J T, Berchuck, A, Spasojevic, I, Clarke-Pearson, D L, Prosnitz, L R, Dewhirst, M W

“…A phase I/II study of Doxil combined with whole abdomen hyperthermia was conducted in patients with refractory ovarian cancer. Liposomal doxorubicin combined…”
Get more information

p53 overexpression in advanced-stage endometrial adenocarcinoma by Kohler, Matthew F., Carney, Pamela, Dodge, Richard, Soper, John T., Clarke-Pearson, Daniel L., Marks, Jeffrey R., Berchuck, Andrew

“…OBJECTIVES: Mutation and overexpression of the p53 tumor suppressor gene in endometrial cancers are associated with advanced stage and poor survival. We sought…”
Get full text

Rectus abdominis myocutaneous flaps for neovaginal reconstruction after radical pelvic surgery by Soper, J T, Havrilesky, L J, Secord, A A, Berchuck, A, Clarke-Pearson, D L

“…The objective of this article is to compare the flap-specific complications associated with vertical (VRAM) and transverse (TRAM) rectus abdominis myocutaneous…”
Get more information

Elevation of multiple serum markers in patients with stage I ovarian cancer by Woolas, R P, Xu, F J, Jacobs, I J, Yu, Y H, Daly, L, Berchuck, A, Soper, J T, Clarke-Pearson, D L, Oram, D H, Bast, Jr, R C

“…The high overall mortality from ovarian cancer (> 60%) relates, in part, to delays in diagnosis. When ovarian cancer is detected in stage I (International…”
Get more information

Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer by Clifford, Susann L., Kaminetsky, Cathy P., Cirisano, Frank D., Dodge, Richard, Soper, John T, Clarke-Pearson, Daniel L

“…OBJECTIVE: This study was conducted to determine whether overexpression of the p53 tumor suppressor gene is associated with poor outcome in early-stage…”
Get full text

Overexpression and mutation of p53 in endometrial carcinoma by KOHLER, M. F, BERCHUCK, A, DAVIDOFF, A. M, HUMPHREY, P. A, DODGE, R. K, IGLEHART, J. D, SOPER, J. T, CLARKE-PEARSON, D. L, BAST, R. C, MARKS, J. R

“…Immunohistochemical staining for the p53 protein was performed in 107 snap frozen primary endometrial adenocarcinomas and 15 benign uterine tissues using…”
Get full text

Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer by Lukes, A S, Kohler, M F, Pieper, C F, Kerns, B J, Bentley, R, Rodriguez, G C, Soper, J T, Clarke-Pearson, D L, Bast, Jr, R C, Berchuck, A

“…Several molecular-genetic alterations in endometrial cancers, including aneuploidy and aberrant expression of p53 and HER-2/neu, have been associated with poor…”
Get more information

Prolonged Oral Etoposide in Recurrent or Advanced Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study by Rose, Peter G., Blessing, John A., Soper, John T., Barter, James F.

“…Objective.In a previous study by the Gynecologic Oncology Group only modest activity was seen with bolus etoposide in leiomyosarcoma of the uterus (an 11%…”
Get full text

Postsurgical Surveillance of Patients with FIGO Stage I/II Endometrial Adenocarcinoma by Berchuck, Andrew, Anspach, Celia, Evans, Anthony C., Soper, John T., Rodriguez, Gustavo C., Dodge, Richard, Robboy, Stanley, Clarke-Pearson, Daniel L.

“…Objective: To examine the effect of postsurgical surveillance on survival of patients with FIGO stage I/II endometrial adenocarcinoma. Methods: We examined the…”
Get full text

Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina by Berchuck, A, Rodriguez, G, Kamel, A, Soper, J T, Clarke-Pearson, D L, Bast, Jr, R C

“…Monoclonal antibodies were used to localize immunohistochemically epidermal growth factor receptor and HER-2/neu in normal and neoplastic frozen tissue samples…”
Get more information

Cervical carcinoma: determination of recurrent tumor extent versus radiation changes with MR imaging by Weber, T M, Sostman, H D, Spritzer, C E, Ballard, R L, Meyer, G A, Clark-Pearson, D L, Soper, J T

“…To evaluate the effectiveness of magnetic resonance (MR) imaging for assessment of the present and extent of tumor recurrence as determined with pathologic and…”
Get more information

Identification and management of high-risk gestational trophoblastic disease by Soper, J T

Get more information